PMID- 29036383
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20240323
IS  - 1745-1701 (Electronic)
IS  - 0586-7614 (Print)
IS  - 0586-7614 (Linking)
VI  - 44
IP  - 3
DP  - 2018 Apr 6
TI  - Nigral Stress-Induced Dopamine Release in Clinical High Risk and 
      Antipsychotic-Naive Schizophrenia.
PG  - 542-551
LID - 10.1093/schbul/sbx042 [doi]
AB  - BACKGROUND: Striatal dopamine (DA) synthesis capacity and release are elevated in 
      schizophrenia (SCZ) and its putative prodrome, the clinical high risk (CHR) 
      state. Striatal DA function results from the activity of midbrain DA neurons 
      projecting mainly from the substantia nigra (SN). Elevated stress-induced DA 
      release in SCZ and CHR was observed in the striatum; however, whether it is also 
      elevated in the SN is unclear. The current study aims to determine whether nigral 
      DA release in response to a validated stress task is altered in CHR and in 
      antipsychotic-naive SCZ. Further, we explore how DA release in the SN and 
      striatum might be related. METHODS: 24 CHR subjects, 9 antipsychotic-naive SCZ 
      and 25 healthy volunteers (HV) underwent 2 positron emission tomography (PET) 
      scans using the DA D2/3 agonist radiotracer, [11C]-(+)-PHNO, which allows 
      simultaneous investigations of DA in the SN and striatum. Psychosocial 
      stress-induced DA release was estimated as the percentage differences in BPND 
      (%[11C]-(+)-PHNO displacement) between stress and sensory-motor control sessions. 
      RESULTS: We observed a significant diagnostic group by session interaction, such 
      that SCZ exhibited greater stress-induced [11C]-(+)-PHNO % displacement (25.90% +/- 
      32.2%; mean +/- SD), as compared to HVs (-10.94% +/- 27.1%). Displacement in CHRs 
      (-1.13% +/- 32.2%) did not differ significantly from either HV or SCZ. CONCLUSION: 
      Our findings suggest that elevated nigral DA responsiveness to stress is observed 
      in antipsychotic-naive SCZ.
FAU - Tseng, Huai-Hsuan
AU  - Tseng HH
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
FAU - Watts, Jeremy J
AU  - Watts JJ
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
AD  - Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, 
      Canada.
FAU - Kiang, Michael
AU  - Kiang M
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
FAU - Suridjan, Ivonne
AU  - Suridjan I
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
FAU - Wilson, Alan A
AU  - Wilson AA
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
AD  - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental 
      Health, Toronto, ON, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
FAU - Houle, Sylvain
AU  - Houle S
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
AD  - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental 
      Health, Toronto, ON, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
FAU - Rusjan, Pablo M
AU  - Rusjan PM
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
AD  - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental 
      Health, Toronto, ON, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
FAU - Mizrahi, Romina
AU  - Mizrahi R
AD  - Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, 
      Canada.
AD  - Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, 
      Canada.
AD  - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental 
      Health, Toronto, ON, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Schizophr Bull
JT  - Schizophrenia bulletin
JID - 0236760
RN  - 0 (Dopamine Agonists)
RN  - 0 (Oxazines)
RN  - 0 (Radiopharmaceuticals)
RN  - 22Z7E0X6OF (naxagolide)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adult
MH  - Corpus Striatum/diagnostic imaging/*metabolism
MH  - Dopamine/*metabolism
MH  - Dopamine Agonists/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Oxazines/*pharmacokinetics
MH  - Positron-Emission Tomography/*methods
MH  - Radiopharmaceuticals/pharmacokinetics
MH  - Risk
MH  - Schizophrenia/diagnostic imaging/*metabolism
MH  - Stress, Psychological/diagnostic imaging/*metabolism
MH  - Substantia Nigra/diagnostic imaging/*metabolism
MH  - Young Adult
PMC - PMC5890468
EDAT- 2017/10/17 06:00
MHDA- 2018/12/12 06:00
PMCR- 2019/04/06
CRDT- 2017/10/17 06:00
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
PHST- 2019/04/06 00:00 [pmc-release]
AID - 3867533 [pii]
AID - sbx042 [pii]
AID - 10.1093/schbul/sbx042 [doi]
PST - ppublish
SO  - Schizophr Bull. 2018 Apr 6;44(3):542-551. doi: 10.1093/schbul/sbx042.